| ||||||
Cancer researchers call for ethnicity to be taken into account |
||||||||||||||||||||||||||||||
|
From EurekAlert! - Breaking News: Breast cancer research needs to investigate how a person's ethnicity influences their response to treatment and its outcome, according to a new Comment piece in today's Lancet (18 July) by researchers from Imperial College London. Emerging evidence suggests that particular drugs may benefit people from one ethnic group more than others, because of differences in their genetic makeup. However, most key trials looking at treatments for breast cancer have been carried out in predominantly white populations in Europe, North America and Australasia. They suggest that clinical trials should record participants' ethnicity and analyse whether there are differences in how patients from particular ethnic groups respond to a particular therapy. The researchers highlight the example of a drug called trasztuzumab, which is commonly used to treat people with breast cancer that is HER-2 positive. The genotype in question is more common in some ethnic groups than in others, so the researchers argue that an individual's ethnicity could be a key factor in determining which treatments are most likely to benefit them. Dr Carlo Palmieri, from the Division of Surgery, Oncology, Reproductive Biology and Anaesthetics at Imperial College London and one of the authors of the piece, said: "Everyone responds differently to treatment and it's often very difficult to predict how well someone will respond to a particular drug. "There are small genetic differences between people from different ethnic backgrounds and it is really important that we find out whether these genetic differences mean that certain drugs perform well in people from certain ethnic groups but not in others. Breast cancer is predominantly a disease of the economically developed world, but rates are rising rapidly in Asian and economically developing countries.
|
| |||||||||||||||||||||||||||||
